|
1
|
Lang AE and Lozano AM: Parkinson’s
disease. First of two parts. N Engl J Med. 339:1044–1053. 1998.
|
|
2
|
Anandhan A, Essa MM and Manivasagam T:
Therapeutic attenuation of neuroinflammation and apoptosis by black
tea theaflavin in chronic MPTP/probenecid model of Parkinson’s
disease. Neurotox Res. 23:166–173. 2013.PubMed/NCBI
|
|
3
|
Barnum CJ and Tansey MG: Neuroinflammation
and non-motor symptoms: the dark passenger of Parkinson’s disease?
Curr Neurol Neurosci Rep. 12:350–358. 2012.PubMed/NCBI
|
|
4
|
Sekiyama K, Sugama S, Fujita M, et al:
Neuroinflammation in Parkinson’s disease and related disorders: A
lesson from genetically manipulated mouse models of
α-synucleinopathies. Parkinsons Dis. 2012:2717322012.
|
|
5
|
Hirsch EC, Vyas S and Hunot S:
Neuroinflammation in Parkinson’s disease. Parkinsonism Relat
Disord. 18(Suppl 1): S210–S212. 2012.
|
|
6
|
Khan MM, Kempuraj D, Thangavel R and
Zaheer A: Protection of MPTP-induced neuroinflammation and
neurodegeneration by Pycnogenol. Neurochem Int. 62:379–388. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghosh A, Kanthasamy A, Joseph J, et al:
Anti-inflammatory and neuroprotective effects of an orally active
apocynin derivative in pre-clinical models of Parkinson’s disease.
J Neuroinflammation. 9:2412012.PubMed/NCBI
|
|
8
|
Yan J, Xu Y, Zhu C, et al: Simvastatin
prevents dopaminergic neurodegeneration in experimental
parkinsonian models: the association with anti-inflammatory
responses. PLoS One. 6:e209452011. View Article : Google Scholar
|
|
9
|
Ghosh A, Roy A, Matras J, Brahmachari S,
Gendelman HE and Pahan K: Simvastatin inhibits the activation of
p21ras and prevents the loss of dopaminergic neurons in a mouse
model of Parkinson’s disease. J Neurosci. 29:13543–13556.
2009.PubMed/NCBI
|
|
10
|
Depboylu C, Stricker S, Ghobril JP, Oertel
WH, Priller J and Höglinger GU: Brain-resident microglia
predominate over infiltrating myeloid cells in activation,
phagocytosis and interaction with T-lymphocytes in the MPTP mouse
model of Parkinson disease. Exp Neurol. 238:183–191. 2012.
View Article : Google Scholar
|
|
11
|
Dutta G, Barber DS, Zhang P, Doperalski NJ
and Liu B: Involvement of dopaminergic neuronal cystatin C in
neuronal injury-induced microglial activation and neurotoxicity. J
Neurochem. 122:752–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Long-Smith CM, Sullivan AM and Nolan YM:
The influence of microglia on the pathogenesis of Parkinson’s
disease. Prog Neurobiol. 89:277–287. 2009.
|
|
13
|
Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu
B and Hong JS: Regional difference in susceptibility to
lipopolysaccharide-induced neurotoxicity in the rat brain: role of
microglia. J Neurosci. 20:6309–6316. 2000.PubMed/NCBI
|
|
14
|
Whitton PS: Inflammation as a causative
factor in the aetiology of Parkinson’s disease. Br J Pharmacol.
150:963–976. 2007.
|
|
15
|
Crotty S, Fitzgerald P, Tuohy E, et al:
Neuroprotective effects of novel phosphatidylglycerol-based
phospholipids in the 6-hydroxydopamine model of Parkinson’s
disease. Eur J Neurosci. 27:294–300. 2008.PubMed/NCBI
|
|
16
|
Mirza B, Hadberg H, Thomsen P and Moos T:
The absence of reactive astrocytosis is indicative of a unique
inflammatory process in Parkinson’s disease. Neuroscience.
95:425–432. 2000.PubMed/NCBI
|
|
17
|
Hunot S, Vila M, Teismann P, et al:
JNK-mediated induction of cyclooxygenase 2 is required for
neurodegeneration in a mouse model of Parkinson’s disease. Proc
Natl Acad Sci USA. 101:665–670. 2004.PubMed/NCBI
|
|
18
|
Arimoto T and Bing G: Up-regulation of
inducible nitric oxide synthase in the substantia nigra by
lipopolysaccharide causes microglial activation and
neurodegeneration. Neurobiol Dis. 12:35–45. 2003. View Article : Google Scholar
|
|
19
|
Bartosz G: Peroxynitrite: mediator of the
toxic action of nitric oxide. Acta Biochim Pol. 43:645–659.
1996.PubMed/NCBI
|
|
20
|
Orr CF, Rowe DB and Halliday GM: An
inflammatory review of Parkinson’s disease. Prog Neurobiol.
68:325–340. 2002.
|
|
21
|
Iravani MM, Leung CC, Sadeghian M, Haddon
CO, Rose S and Jenner P: The acute and the long-term effects of
nigral lipopolysaccharide administration on dopaminergic
dysfunction and glial cell activation. Eur J Neurosci. 22:317–330.
2005. View Article : Google Scholar
|
|
22
|
McLaughlin P, Zhou Y, Ma T, et al:
Proteomic analysis of microglial contribution to mouse
strain-dependent dopaminergic neurotoxicity. Glia. 53:567–582.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wersinger C and Sidhu A: An inflammatory
pathomechanism for Parkinson’s disease? Curr Med Chem. 13:591–602.
2006.
|
|
24
|
Stoll G, Jander S and Schroeter M:
Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J
Neural Transm Suppl. 59:81–89. 2000.PubMed/NCBI
|
|
25
|
Wang DD and Bordey A: The astrocyte
odyssey. Prog Neurobiol. 86:342–367. 2008.
|
|
26
|
Vila M, Jackson-Lewis V, Guégan C, et al:
The role of glial cells in Parkinson’s disease. Curr Opin Neurol.
14:483–489. 2001.
|
|
27
|
Ortinski PI, Dong J, Mungenast A, et al:
Selective induction of astrocytic gliosis generates deficits in
neuronal inhibition. Nat Neurosci. 13:584–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mythri RB, Venkateshappa C, Harish G, et
al: Evaluation of markers of oxidative stress, antioxidant function
and astrocytic proliferation in the striatum and frontal cortex of
Parkinson’s disease brains. Neurochem Res. 36:1452–1463.
2011.PubMed/NCBI
|
|
29
|
Aoki E, Yano R, Yokoyama H, Kato H and
Araki T: Role of nuclear transcription factor kappa B (NF-kappaB)
for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced
apoptosis in nigral neurons of mice. Exp Mol Pathol. 86:57–64.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saura J, Parés M, Bové J, et al:
Intranigral infusion of interleukin-1beta activates astrocytes and
protects from subsequent 6-hydroxydopamine neurotoxicity. J
Neurochem. 85:651–661. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bélanger M and Magistretti PJ: The role of
astroglia in neuroprotection. Dialogues Clin Neurosci. 11:281–295.
2009.
|
|
32
|
Sortwell CE, Daley BF, Pitzer MR, McGuire
SO, Sladek JR Jr and Collier TJ: Oligodendrocyte-type 2
astrocyte-derived trophic factors increase survival of developing
dopamine neurons through the inhibition of apoptotic cell death. J
Comp Neurol. 426:143–153. 2000. View Article : Google Scholar
|
|
33
|
Dong Y and Benveniste EN: Immune function
of astrocytes. Glia. 36:180–190. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Q, Tang XN and Yenari MA: The
inflammatory response in stroke. J Neuroimmunol. 184:53–68. 2007.
View Article : Google Scholar
|
|
35
|
Gomide V, Bibancos T and Chadi G: Dopamine
cell morphology and glial cell hypertrophy and process branching in
the nigrostriatal system after striatal 6-OHDA analyzed by specific
sterological tools. Int J Neurosci. 115:557–582. 2005. View Article : Google Scholar
|
|
36
|
Wakabayashi K, Hayashi S, Yoshimoto M,
Kudo H and Takahashi H: NACP/alpha-synuclein-positive filamentous
inclusions in astrocytes and oligodendrocytes of Parkinson’s
disease brains. Acta Neuropathol. 99:14–20. 2000.PubMed/NCBI
|
|
37
|
Benarroch EE: Oligodendrocytes:
Susceptibility to injury and involvement in neurologic disease.
Neurology. 72:1779–1785. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Khan O, Filippi M, Freedman MS, et al:
Chronic cerebrospinal venous insufficiency and multiple sclerosis.
Ann Neurol. 67:286–290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takagi S, Hayakawa N, Kimoto H, Kato H and
Araki T: Damage to oligodendrocytes in the striatum after MPTP
neurotoxicity in mice. J Neural Transm. 114:1553–1557. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rosin C, Colombo S, Calver AA, Bates TE
and Skaper SD: Dopamine D2 and D3 receptor agonists limit
oligodendrocyte injury caused by glutamate oxidative stress and
oxygen/glucose deprivation. Glia. 52:336–343. 2005. View Article : Google Scholar
|
|
41
|
McTigue DM and Tripathi RB: The life,
death, and replacement of oligodendrocytes in the adult CNS. J
Neurochem. 107:1–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kurkowska-Jastrzebska I, Bałkowiec-Iskra
E, Ciesielska A, et al: Decreased inflammation and augmented
expression of trophic factors correlate with MOG-induced
neuroprotection of the injured nigrostriatal system in the murine
MPTP model of Parkinson’s disease. Int Immunopharmacol. 9:781–791.
2009.
|
|
43
|
Zhao C, Ling Z, Newman MB, Bhatia A and
Carvey PM: TNF-alpha knockout and minocycline treatment attenuates
blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis.
26:36–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pieper HC, Evert BO, Kaut O, Riederer PF,
Waha A and Wüllner U: Different methylation of the TNF-alpha
promoter in cortex and substantia nigra: Implications for selective
neuronal vulnerability. Neurobiol Dis. 32:521–527. 2008. View Article : Google Scholar
|
|
45
|
Rousselet E, Callebert J, Parain K, et al:
Role of TNF-alpha receptors in mice intoxicated with the
parkinsonian toxin MPTP. Exp Neurol. 177:183–192. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Boka G, Anglade P, Wallach D, Javoy-Agid,
et al: Immunocytochemical analysis of tumor necrosis factor and its
receptors in Parkinson’s disease. Neurosci Lett. 172:151–154.
1994.PubMed/NCBI
|
|
47
|
Sriram K, Matheson JM, Benkovic SA, Miller
DB, Luster MI and O’Callaghan JP: Deficiency of TNF receptors
suppresses microglial activation and alters the susceptibility of
brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
FASEB J. 20:670–682. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sriram K, Matheson JM, Benkovic SA, Miller
DB, Luster MI and O’Callaghan JP: Mice deficient in TNF receptors
are protected against dopaminergic neurotoxicity: implications for
Parkinson’s disease. FASEB J. 16:1474–1476. 2002.PubMed/NCBI
|
|
49
|
McCoy MK, Martinez TN, Ruhn KA, et al:
Blocking soluble tumor necrosis factor signaling with
dominant-negative tumor necrosis factor inhibitor attenuates loss
of dopaminergic neurons in models of Parkinson’s disease. J
Neurosci. 26:9365–9375. 2006.
|
|
50
|
Scalzo P, Kümmer A, Cardoso F and Teixeira
AL: Serum levels of interleukin-6 are elevated in patients with
Parkinson’s disease and correlate with physical performance.
Neurosci Lett. 468:56–58. 2010.PubMed/NCBI
|
|
51
|
Wu DC, Jackson-Lewis V, Vila M, et al:
Blockade of microglial activation is neuroprotective in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of
Parkinson disease. J Neurosci. 22:1763–1771. 2002.PubMed/NCBI
|
|
52
|
Ferrari CC, Pott Godoy MC, Tarelli R,
Chertoff M, Depino AM and Pitossi FJ: Progressive neurodegeneration
and motor disabilities induced by chronic expression of IL-1beta in
the substantia nigra. Neurobiol Dis. 24:183–193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Machado A, Herrera AJ, Venero JL, et al:
inflammatory animal model for Parkinson’s disease: the intranigral
injection of lps induced the inflammatory process along with the
selective degeneration of nigrostriatal dopaminergic neurons. ISRN
Neurol. 2011:4761582011.
|
|
54
|
Sawada M, Imamura K and Nagatsu T: Role of
cytokines in inflammatory process in Parkinson’s disease. J Neural
Transm Suppl. 70:373–381. 2006.
|
|
55
|
Nagatsu T and Sawada M: Inflammatory
process in Parkinson’s disease: role for cytokines. Curr Pharm Des.
11:999–1016. 2005.
|
|
56
|
Mount MP, Lira A, Grimes D, et al:
Involvement of interferon-gamma in microglial-mediated loss of
dopaminergic neurons. J Neurosci. 27:3328–3337. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Litteljohn D, Mangano E, Shukla N and
Hayley S: Interferon-gamma deficiency modifies the motor and
co-morbid behavioral pathology and neurochemical changes provoked
by the pesticide paraquat. Neuroscience. 164:1894–1906. 2009.
View Article : Google Scholar
|
|
58
|
Mogi M, Kondo T, Mizuno Y and Nagatsu T:
p53 protein, interferon-gamma, and NF-kappaB levels are elevated in
the parkinsonian brain. Neurosci Lett. 414:94–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen H, O’Reilly EJ, Schwarzschild MA and
Ascherio A: Peripheral inflammatory biomarkers and risk of
Parkinson’s disease. Am J Epidemiol. 167:90–95. 2008.
|
|
60
|
Gonzalez-Aparicio R, Flores JA and
Fernandez-Espejo EE: Antiparkinsonian trophic action of glial cell
line-derived neurotrophic factor and transforming growth factor
beta1 is enhanced after co-infusion in rats. Exp Neurol.
226:136–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rota E, Bellone G, Rocca P, Bergamasco B,
Emanuelli G and Ferrero P: Increased intrathecal TGF-beta1, but not
IL-12, IFN-gamma and IL-10 levels in Alzheimer’s disease patients.
Neurol Sci. 27:33–39. 2006.
|
|
62
|
Rentzos M, Nikolaou C, Andreadou E, et al:
Circulating interleukin-10 and interleukin-12 in Parkinson’s
disease. Acta Neurol Scand. 119:332–337. 2009.PubMed/NCBI
|
|
63
|
Arimoto T, Choi DY, Lu X, et al:
Interleukin-10 protects against inflammation-mediated degeneration
of dopaminergic neurons in substantia nigra. Neurobiol Aging.
28:894–906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Qian L, Block ML, Wei SJ, et al:
Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in
primary midbrain cultures by inhibiting the function of NADPH
oxidase. J Pharmacol Exp Ther. 319:44–52. 2006. View Article : Google Scholar
|
|
65
|
Sánchez-Capelo A, Colin P, Guibert B,
Biguet NF and Mallet J: Transforming growth factor beta 1
overexpression in the nigrostriatal system increases the
dopaminergic deficit of MPTP mice. Mol Cell Neurosci. 23:614–625.
2003.PubMed/NCBI
|
|
66
|
Qian L, Wei SJ, Zhang D, et al: Potent
anti-inflammatory and neuroprotective effects of TGF-beta 1 are
mediated through the inhibition of ERK and
p47PHOX-Ser345 phosphorylation and
translocation in microglia. J Immunol. 181:660–668. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ross OA, O’Neill C, Rea IM, et al:
Functional promoter region polymorphism of the proinflammatory
chemokine IL-8 gene associates with Parkinson’s disease in the
Irish. Hum Immunol. 65:340–346. 2004.PubMed/NCBI
|
|
68
|
Nishimura M, Kuno S, Mizuta I, et al:
Influence of monocyte chemoattractant protein 1 gene polymorphism
on age at onset of sporadic Parkinson’s disease. Mov Disord.
18:953–955. 2003.PubMed/NCBI
|
|
69
|
Shimoji M, Pagan F, Healton EB and
Mocchetti I: CXCR4 and CXCL12 expression is increased in the
nigro-striatal system of Parkinson’s disease. Neurotox Res.
16:318–328. 2009.PubMed/NCBI
|
|
70
|
Edman LC, Mira H, Erices A, et al:
Alpha-chemokines regulate proliferation, neurogenesis, and
dopaminergic differentiation of ventral midbrain precursors and
neurospheres. Stem Cells. 26:1891–1900. 2008. View Article : Google Scholar
|
|
71
|
Tsai SJ, Chao CY and Yin MC: Preventive
and therapeutic effects of caffeic acid against inflammatory injury
in striatum of MPTP-treated mice. Eur J Pharmacol. 670:441–447.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang Q, Zheng H, Zhang ZF and Zhang YX:
Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra
of mice with MPTP-induced Parkinson disease through the P38
signaling pathway. Nan Fang Yi Ke Da Xue Xue Bao. 28:1594–1598.
2008.(In Chinese).
|
|
73
|
Wang Y, Zhang Y, Wei Z, Li H, Zhou H and
Zhang Z and Zhang Z: JNK inhibitor protects dopaminergic neurons by
reducing COX-2 expression in the MPTP mouse model of subacute
Parkinson’s disease. J Neurol Sci. 285:172–177. 2009.PubMed/NCBI
|
|
74
|
Gupta A, Dhir A, Kumar A and Kulkarni SK:
Protective effect of cyclooxygenase (COX)-inhibitors against
drug-induced catatonia and MPTP-induced striatal lesions in rats.
Pharmacol Biochem Behav. 94:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Moghaddam HF, Hemmati A, Nazari Z, Mehrab
H, Abid KM and Ardestani MS: Effects of aspirin and celecoxib on
rigidity in a rat model of Parkinson’s disease. Pak J Biol Sci.
10:3853–3858. 2007.PubMed/NCBI
|
|
76
|
Litteljohn D, Mangano EN and Hayley S:
Cyclooxygenase-2 deficiency modifies the neurochemical effects,
motor impairment and co-morbid anxiety provoked by paraquat
administration in mice. Eur J Neurosci. 28:707–716. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hoang T, Choi DK, Nagai M, et al: Neuronal
NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model
of Parkinson disease. Free Radic Biol Med. 47:1049–1056. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
McClain JA, Phillips LL and Fillmore HL:
Increased MMP-3 and CTGF expression during
lipopolysaccharide-induced dopaminergic neurodegeneration. Neurosci
Lett. 460:27–31. 2009. View Article : Google Scholar
|
|
79
|
Kim EM and Hwang O: Role of matrix
metalloproteinase-3 in neurodegeneration. J Neurochem. 116:22–32.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Shin EJ, Kim EM, Lee JA, Rhim H and Hwang
O: Matrix metalloproteinase-3 is activated by HtrA2/Omi in
dopaminergic cells: relevance to Parkinson’s disease. Neurochem
Int. 60:249–256. 2012.PubMed/NCBI
|
|
81
|
Kim YS, Kim SS, Cho JJ, et al: Matrix
metalloproteinase-3: a novel signaling proteinase from apoptotic
neuronal cells that activates microglia. J Neurosci. 25:3701–3711.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Choi DH, Kim YJ, Kim YG, Joh TH, Beal MF
and Kim YS: Role of matrix metalloproteinase 3-mediated
alpha-synuclein cleavage in dopaminergic cell death. J Biol Chem.
286:14168–14177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kim YS, Choi DH, Block ML, et al: A
pivotal role of matrix metalloproteinase-3 activity in dopaminergic
neuronal degeneration via microglial activation. FASEB J.
21:179–187. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Choi DH, Kim EM, Son HJ, et al: A novel
intracellular role of matrix metalloproteinase-3 during apoptosis
of dopaminergic cells. J Neurochem. 106:405–415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lorenzl S, Albers DS, Narr S, Chirichigno
J and Beal MF: Expression of MMP-2, MMP-9, and MMP-1 and their
endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain
tissue of Parkinson’s disease. Exp Neurol. 178:13–20.
2002.PubMed/NCBI
|
|
86
|
Lorenzl S, Calingasan N, Yang L, et al:
Matrix metalloproteinase-9 is elevated in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism
in mice. Neuromolecular Med. 5:119–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Nomura N, Miyajima N, Sazuka T, et al:
Prediction of the coding sequences of unidentified human genes. I
The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by
analysis of randomly sampled cDNA clones from human immature
myeloid cell line KG-1 (supplement). DNA Res. 1:47–56. 1994.
View Article : Google Scholar
|
|
88
|
Tabeta K, Georgel P, Janssen E, et al:
Toll-like receptors 9 and 3 as essential components of innate
immune defense against mouse cytomegalovirus infection. Proc Natl
Acad Sci USA. 101:3516–3521. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Atkinson TJ: Toll-like receptors,
transduction-effector pathways, and disease diversity: evidence of
an immunobiological paradigm explaining all human illness? Int Rev
Immunol. 27:255–281. 2008. View Article : Google Scholar
|
|
90
|
Bsibsi M, Ravid R, Gveric D and van Noort
JM: Broad expression of Toll-like receptors in the human central
nervous system. J Neuropathol Exp Neurol. 61:1013–1021.
2002.PubMed/NCBI
|
|
91
|
Lehnardt S, Massillon L, Follett P, et al:
Activation of innate immunity in the CNS triggers neurodegeneration
through a Toll-like receptor 4-dependent pathway. Proc Natl Acad
Sci USA. 100:8514–8519. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Panaro MA, Lofrumento DD, Saponaro C, et
al: Expression of TLR4 and CD14 in the central nervous system (CNS)
in a MPTP mouse model of Parkinson’s-like disease. Immunopharmacol
Immunotoxicol. 30:729–740. 2008.PubMed/NCBI
|
|
93
|
Noelker C, Morel L, Lescot T, et al: Toll
like receptor 4 mediates cell death in a mouse MPTP model of
Parkinson disease. Sci Rep. 3:13932013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kim C, Ho DH, Suk JE, et al:
Neuron-released oligomeric α-synuclein is an endogenous agonist of
TLR2 for paracrine activation of microglia. Nat Commun.
4:15622013.PubMed/NCBI
|
|
95
|
Letiembre M, Liu Y, Walter S, et al:
Screening of innate immune receptors in neurodegenerative diseases:
a similar pattern. Neurobiol Aging. 30:759–768. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Groemping Y and Rittinger K: Activation
and assembly of the NADPH oxidase: a structural perspective.
Biochem J. 386:401–416. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Babior BM: NADPH oxidase: an update.
Blood. 93:1464–1476. 1999.PubMed/NCBI
|
|
98
|
Anantharam V, Kaul S, Song C, Kanthasamy A
and Kanthasamy AG: Pharmacological inhibition of neuronal NADPH
oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced
oxidative stress and apoptosis in mesencephalic dopaminergic
neuronal cells. Neurotoxicology. 28:988–997. 2007. View Article : Google Scholar
|
|
99
|
Cristóvão AC, Choi DH, Baltazar G, Beal MF
and Kim YS: The role of NADPH oxidase 1-derived reactive oxygen
species in paraquat-mediated dopaminergic cell death. Antioxid
Redox Signal. 11:2105–2118. 2009.PubMed/NCBI
|
|
100
|
Wu DC, Teismann P, Tieu K, et al: NADPH
oxidase mediates oxidative stress in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s
disease. Proc Natl Acad Sci USA. 100:6145–6150. 2003.
|
|
101
|
Liangliang X, Yonghui H, Shunmei E,
Shoufang G, Wei Z and Jiangying Z: Dominant-positive HSF1 decreases
alpha-synuclein level and alpha-synuclein-induced toxicity. Mol
Biol Rep. 37:1875–1881. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Benn SC and Woolf CJ: Adult neuron
survival strategies - slamming on the brakes. Nat Rev Neurosci.
5:686–700. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Meriin AB and Sherman MY: Role of
molecular chaperones in neurodegenerative disorders. Int J
Hyperthermia. 21:403–419. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Auluck PK, Chan HY, Trojanowski JQ, Lee VM
and Bonini NM: Chaperone suppression of alpha-synuclein toxicity in
a Drosophila model for Parkinson’s disease. Science. 295:865–868.
2002.PubMed/NCBI
|
|
105
|
Tantucci M, Mariucci G, Taha E, et al:
Induction of heat shock protein 70 reduces the alteration of
striatal electrical activity caused by mitochondrial impairment.
Neuroscience. 163:735–740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Pan T, Li X, Xie W, Jankovic J and Le W:
Valproic acid-mediated Hsp70 induction and anti-apoptotic
neuroprotection in SH-SY5Y cells. FEBS Lett. 579:6716–6720. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Shen HY, He JC, Wang Y, Huang QY and Chen
JF: Geldanamycin induces heat shock protein 70 and protects against
MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem.
280:39962–39969. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Dedmon MM, Christodoulou J, Wilson MR and
Dobson CM: Heat shock protein 70 inhibits alpha-synuclein fibril
formation via preferential binding to prefibrillar species. J Biol
Chem. 280:14733–14740. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Liu M, Aneja R, Sun X, et al: Parkin
regulates Eg5 expression by Hsp70 ubiquitination-dependent
inactivation of c-Jun NH2-terminal kinase. J Biol Chem.
283:35783–35788. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Uryu K, Richter-Landsberg C, Welch W, et
al: Convergence of heat shock protein 90 with ubiquitin in
filamentous alpha-synuclein inclusions of alpha-synucleinopathies.
Am J Pathol. 168:947–961. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Calabrese V, Mancuso C, Ravagna A, et al:
In vivo induction of heat shock proteins in the substantia nigra
following L-DOPA administration is associated with increased
activity of mitochondrial complex I and nitrosative stress in rats:
regulation by glutathione redox state. J Neurochem. 101:709–717.
2007. View Article : Google Scholar
|
|
112
|
Kulathingal J, Ko LW, Cusack B and Yen SH:
Proteomic profiling of phosphoproteins and glycoproteins responsive
to wild-type alpha-synuclein accumulation and aggregation. Biochim
Biophys Acta. 1794:211–224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wang L, Xie C, Greggio E, et al: The
chaperone activity of heat shock protein 90 is critical for
maintaining the stability of leucine-rich repeat kinase 2. J
Neurosci. 28:3384–3391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Liu J, Zhang JP, Shi M, et al: Rab11a and
HSP90 regulate recycling of extracellular alpha-synuclein. J
Neurosci. 29:1480–1485. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Cassarino DS, Halvorsen EM, Swerdlow RH,
et al: Interaction among mitochondria, mitogen-activated protein
kinases, and nuclear factor-kappaB in cellular models of
Parkinson’s disease. J Neurochem. 74:1384–1392. 2000.PubMed/NCBI
|
|
116
|
Wilms H, Rosenstiel P, Sievers J, Deuschl
G, Zecca L and Lucius R: Activation of microglia by human
neuromelanin is NF-kappaB dependent and involves p38
mitogen-activated protein kinase: implications for Parkinson’s
disease. FASEB J. 17:500–502. 2003.PubMed/NCBI
|
|
117
|
Yang HJ, Wang L, Xia YY, Chang PN and Feng
ZW: NF-kappaB mediates MPP+ induced apoptotic cell death in
neuroblastoma cells SH-EP1 through JNK and c-Jun/AP-1. Neurochem
Int. 56:128–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Panet H, Barzilai A, Daily D, Melamed E
and Offen D: Activation of nuclear transcription factor kappa B
(NF-kappaB) is essential for dopamine-induced apoptosis in PC12
cells. J Neurochem. 77:391–398. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wang X, Qin ZH, Leng Y, et al:
Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y
cells. J Neurochem. 83:1094–1102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Weingarten P, Bermak J and Zhou QY:
Evidence for non-oxidative dopamine cytotoxicity: potent activation
of NF-kappa B and lack of protection by anti-oxidants. J Neurochem.
76:1794–1804. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kenchappa RS and Ravindranath V:
Glutaredoxin is essential for maintenance of brain mitochondrial
complex I: studies with MPTP. FASEB J. 17:717–719. 2003.PubMed/NCBI
|
|
122
|
Liang ZQ, Li YL, Zhao XL, et al: NF-kappaB
contributes to 6-hydroxydopamine-induced apoptosis of nigral
dopaminergic neurons through p53. Brain Res. 1145:190–203. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Williams CA, Lin Y, Maynard A and Cheng
SY: Involvement of NF kappa B in potentiated effect of
mn-containing dithiocarbamates on MPP(+) induced cell death. Cell
Mol Neurobiol. 33:815–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Pranski E, Van Sanford CD, Dalal N, et al:
NF-κB activity is inversely correlated to RNF11 expression in
Parkinson’s disease. Neurosci Lett. 547:16–20. 2013.
|
|
125
|
Dehmer T, Heneka MT, Sastre M, Dichgans J
and Schulz JB: Protection by pioglitazone in the MPTP model of
Parkinson’s disease correlates with I kappa B alpha induction and
block of NF kappa B and iNOS activation. J Neurochem. 88:494–501.
2004.PubMed/NCBI
|
|
126
|
Ghosh A, Roy A, Liu X, et al: Selective
inhibition of NF-kappaB activation prevents dopaminergic neuronal
loss in a mouse model of Parkinson’s disease. Proc Natl Acad Sci
USA. 104:18754–18759. 2007.PubMed/NCBI
|
|
127
|
Soós J, Engelhardt JI, Siklós L, Havas L
and Majtényi K: The expression of PARP, NF-kappa B and parvalbumin
is increased in Parkinson disease. Neuroreport. 15:1715–1718.
2004.PubMed/NCBI
|
|
128
|
Cao JP, Wang HJ, Yu JK, Liu HM and Gao DS:
The involvement of NF-kappaB p65/p52 in the effects of GDNF on DA
neurons in early PD rats. Brain Res Bull. 76:505–511. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang J, Du XX, Jiang H and Xie JX:
Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by
anti-oxidation and nuclear factor-kappa B modulation in MES23.5
cells. Biochem Pharmacol. 78:178–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Bonifati V, Rizzu P, Squitieri F, et al:
DJ-1 (PARK7), a novel gene for autosomal recessive, early onset
parkinsonism. Neurol Sci. 24:159–160. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Taira T, Saito Y, Niki T, Iguchi-Ariga SM,
Takahashi K and Ariga H: DJ-1 has a role in antioxidative stress to
prevent cell death. EMBO Rep. 5:213–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Inden M, Taira T, Kitamura Y, et al: PARK7
DJ-1 protects against degeneration of nigral dopaminergic neurons
in Parkinson’s disease rat model. Neurobiol Dis. 24:144–158.
2006.PubMed/NCBI
|
|
133
|
Yanagida T, Takata K, Inden M, et al:
Distribution of DJ-1, Parkinson’s disease-related protein PARK7,
and its alteration in 6-hydroxydopamine-treated hemiparkinsonian
rat brain. J Pharmacol Sci. 102:243–247. 2006.
|
|
134
|
Yanagisawa D, Kitamura Y, Inden M, et al:
DJ-1 protects against neurodegeneration caused by focal cerebral
ischemia and reperfusion in rats. J Cereb Blood Flow Metab.
28:563–578. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhou W and Freed CR: DJ-1 up-regulates
glutathione synthesis during oxidative stress and inhibits A53T
alpha-synuclein toxicity. J Biol Chem. 280:43150–43158. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lavara-Culebras E and Paricio N:
Drosophila DJ-1 mutants are sensitive to oxidative stress and show
reduced lifespan and motor deficits. Gene. 400:158–165. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Andres-Mateos E, Perier C, Zhang L, et al:
DJ-1 gene deletion reveals that DJ-1 is an atypical
peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA.
104:14807–14812. 2007. View Article : Google Scholar
|
|
138
|
Goldberg MS, Pisani A, Haburcak M, et al:
Nigrostriatal dopaminergic deficits and hypokinesia caused by
inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron.
45:489–496. 2005. View Article : Google Scholar
|
|
139
|
Kim RH, Smith PD, Aleyasin H, et al:
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad
Sci USA. 102:5215–5220. 2005. View Article : Google Scholar
|
|
140
|
Chen L, Cagniard B, Mathews T, et al:
Age-dependent motor deficits and dopaminergic dysfunction in DJ-1
null mice. J Biol Chem. 280:21418–21426. 2005. View Article : Google Scholar
|
|
141
|
Yamaguchi H and Shen J: Absence of
dopaminergic neuronal degeneration and oxidative damage in aged
DJ-1-deficient mice. Mol Neurodegener. 2:102007. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Waak J, Weber SS, Görner K, et al:
Oxidizable residues mediating protein stability and cytoprotective
interaction of DJ-1 with apoptosis signal-regulating kinase 1. J
Biol Chem. 284:14245–14257. 2009. View Article : Google Scholar
|
|
143
|
Chandran JS, Lin X, Zapata A, et al:
Progressive behavioral deficits in DJ-1-deficient mice are
associated with normal nigrostriatal function. Neurobiol Dis.
29:505–514. 2008. View Article : Google Scholar
|
|
144
|
Mullett SJ, Hamilton RL and Hinkle DA:
DJ-1 immunoreactivity in human brain astrocytes is dependent on
infarct presence and infarct age. Neuropathology. 29:125–131. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Mullett SJ and Hinkle DA: DJ-1 knock-down
in astrocytes impairs astrocyte-mediated neuroprotection against
rotenone. Neurobiol Dis. 33:28–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Kang WY, Yang Q, Jiang XF, et al: Salivary
DJ-1 could be an indicator of Parkinson’s disease progression.
Front Aging Neurosci. 6:1022014.PubMed/NCBI
|
|
147
|
Shadrach KG, Rayborn ME, Hollyfield JG and
Bonilha VL: DJ-1-dependent regulation of oxidative stress in the
retinal pigment epithelium (RPE). PLoS One. 8:e679832013.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Liu F, Nguyen JL, Hulleman JD, Li L and
Rochet JC: Mechanisms of DJ-1 neuroprotection in a cellular model
of Parkinson’s disease. J Neurochem. 105:2435–2453. 2008.PubMed/NCBI
|
|
149
|
Neumann M, Müller V, Görner K, Kretzschmar
HA, Haass C and Kahle PJ: Pathological properties of the
Parkinson’s disease-associated protein DJ-1 in
alpha-synucleinopathies and tauopathies: relevance for multiple
system atrophy and Pick’s disease. Acta Neuropathol. 107:489–496.
2004.
|
|
150
|
Waragai M, Wei J, Fujita M, et al:
Increased level of DJ-1 in the cerebrospinal fluids of sporadic
Parkinson’s disease. Biochem Biophys Res Commun. 345:967–972.
2006.PubMed/NCBI
|
|
151
|
Kumaran R, Vandrovcova J, Luk C, et al:
Differential DJ-1 gene expression in Parkinson’s disease. Neurobiol
Dis. 36:393–400. 2009.
|
|
152
|
Nural H, He P, Beach T, Sue L, Xia W and
Shen Y: Dissembled DJ-1 high molecular weight complex in cortex
mitochondria from Parkinson’s disease patients. Mol Neurodegener.
4:232009.
|
|
153
|
Xie Z, Zhuang X and Chen L: DJ-1 mRNA
anatomical localization and cell type identification in the mouse
brain. Neurosci Lett. 465:214–219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Lev N, Roncevic D, Ickowicz D, Melamed E
and Offen D: Role of DJ-1 in Parkinson’s disease. J Mol Neurosci.
29:215–225. 2006.
|
|
155
|
Lev N, Ickowicz D, Barhum Y, Lev S,
Melamed E and Offen D: DJ-1 protects against dopamine toxicity. J
Neural Transm. 116:151–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Pei L, Castrillo A and Tontonoz P:
Regulation of macrophage inflammatory gene expression by the orphan
nuclear receptor Nur77. Mol Endocrinol. 20:786–794. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Doi Y, Oki S, Ozawa T, Hohjoh H, Miyake S
and Yamamura T: Orphan nuclear receptor NR4A2 expressed in T cells
from multiple sclerosis mediates production of inflammatory
cytokines. Proc Natl Acad Sci USA. 105:8381–8386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Pei L, Castrillo A, Chen M, Hoffmann A and
Tontonoz P: Induction of NR4A orphan nuclear receptor expression in
macrophages in response to inflammatory stimuli. J Biol Chem.
280:29256–29262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Maheux J, Ethier I, Rouillard C and
Lévesque D: Induction patterns of transcription factors of the nur
family (nurr1, nur77, and nor-1) by typical and atypical
antipsychotics in the mouse brain: implication for their mechanism
of action. J Pharmacol Exp Ther. 313:460–473. 2005. View Article : Google Scholar
|
|
160
|
Gilbert F, Morissette M, St-Hilaire M, et
al: Nur77 gene knockout alters dopamine neuron biochemical activity
and dopamine turnover. Biol Psychiatry. 60:538–547. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Jankovic J, Chen S and Le WD: The role of
Nurr1 in the development of dopaminergic neurons and Parkinson’s
disease. Prog Neurobiol. 77:128–138. 2005.
|
|
162
|
Pan T, Zhu W, Zhao H, et al: Nurr1
deficiency predisposes to lactacystin-induced dopaminergic neuron
injury in vitro and in vivo. Brain Res. 1222:222–229. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Fan X, Luo G, Ming M, et al: Nurr1
expression and its modulation in microglia. Neuroimmunomodulation.
16:162–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Bensinger SJ and Tontonoz P: A Nurr1
pathway for neuroprotection. Cell. 137:26–28. 2009. View Article : Google Scholar : PubMed/NCBI
|
